SYS6010 is an antibody-drug conjugate (ADC) targeting epidermal growth factor receptor ( EGFR ), which is formed by conjugating the anti-EGFR humanized IgG1 monoclonal antibody Becotatug with the topoisomerase I inhibitor JS-1 via a cleavable tetrapeptide linker. SYS6010 can be used in the research of advanced solid tumors such as non-small cell lung cancer [1] [2].
In Vitro, SYS6010 undergoes endocytosis, and its linker is cleaved by proteases to release the payload, thereby exerting anticancer effects after binding to EGFR on the surface of tumor cells[1][2].
References:
[1]. Lu, S., et al. (2025). Abstract CT008: First-in-human study of SYS6010, a novel EGFR targeting antibody drug conjugate (ADC) for patients with advanced solid tumors. Cancer Research, 85(8_Supplement_2), CT008-CT008.
[2]. Lu, S., et al. M.,... & Yang, Y. (2025). Abstract CT008: First-in-human study of SYS6010, a novel EGFR targeting antibody drug conjugate (ADC) for patients with advanced solid tumors. Cancer Research, 85(8_Supplement_2), CT008-CT008.
In Vitro, SYS6010 undergoes endocytosis, and its linker is cleaved by proteases to release the payload, thereby exerting anticancer effects after binding to EGFR on the surface of tumor cells[1][2].
References:
[1]. Lu, S., et al. (2025). Abstract CT008: First-in-human study of SYS6010, a novel EGFR targeting antibody drug conjugate (ADC) for patients with advanced solid tumors. Cancer Research, 85(8_Supplement_2), CT008-CT008.
[2]. Lu, S., et al. M.,... & Yang, Y. (2025). Abstract CT008: First-in-human study of SYS6010, a novel EGFR targeting antibody drug conjugate (ADC) for patients with advanced solid tumors. Cancer Research, 85(8_Supplement_2), CT008-CT008.